Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2007.091975v1, 2008; 10.1373/clinchem.2007.091975
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.091975v1
54/4/673    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitsuhashi, M.
Right arrow Articles by Shinagawa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitsuhashi, M.
Right arrow Articles by Shinagawa, A.

Received on May 11, 2007
Accepted on January 21, 2008

Molecular Diagnostics and Genetics

Ex Vivo Simulation of the Action of Antileukemia Drugs by Measuring Apoptosis-Related mRNA in Blood

Masato Mitsuhashi 1*, Katsuya Endo 2, Kazuhiko Obara 2, Hiroshi Izutsu 2, Taishi Ishida 3, Norio Chikatsu 3, Atsushi Shinagawa 3

1 Hitachi Chemical Research Center, Inc., Irvine, CA, and Hitachi Chemical Co., Ltd., Hitachi, Japan
2 Hitachi Chemical Co., Ltd., Hitachi, Japan
3 Hitachi Ltd., Hitachi General Hospital, Hitachi, Japan

* To whom correspondence should be addressed. E-mail: mmitsuhashi{at}HCRcenter.com.

BACKGROUND: In conventional bioassays, isolated cells are suspended in culture media, incubated in vitro for several days, and then characterized with respect to any cellular changes. In developing new molecular tests under physiological ex vivo conditions, we quantified the production of mRNAs for p21 and PUMA (p53 up-regulated modulator of apoptosis), which are involved in cell cycle arrest and apoptosis, respectively.

METHODS: We stimulated human whole blood with a chemotherapeutic drug (cytarabine, daunorubicin, mitoxantrone, aclarubicin, etoposide, or idarubicin) for 4 h and then quantified mRNA by assessing mRNA recovery and cDNA-synthesis efficiency in each sample. We also used immunoassay and flow cytometry to investigate nucleosome and annexin V, respectively, as apoptosis markers.

RESULTS: Ex vivo mRNA analysis yielded more positive results than nucleosome and annexin V analyses. The concentrations of cytarabine- and daunorubicin-induced p21 and PUMA mRNAs were significantly lower in acute myelogenous leukemia (AML) patients than in healthy controls (P <0.0001), whereas idarubicin induced significantly greater responses in AML patients than in controls (P = 0.01). The patients had different mRNA-response patterns, which were largely classifiable into 4 groups. Prednisone enhanced cytarabine or mitoxantrone induction of p21 and PUMA mRNAs in 3 (2.6%) of 114 reactions. All 15 patients who achieved complete remission had received at least one drug that produced positive mRNA responses, whereas we observed a lack of mRNA response to the clinically used drugs in all 3 cases in which the therapy failed to induce any hematologic improvement.

CONCLUSION: This study introduced ex vivo mRNA analysis as a candidate platform for drug-sensitivity tests in leukemia.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Association for Clinical Chemistry.